AV 7909

Next Previous
Drug Profile

AV 7909

Alternative Names: AV7909; BioThrax + agatolimod; NuThrax; Third-generation anthrax vaccine candidate (BioThrax + CPG 7909) - Emergent BioSolutions

Latest Information Update: 15 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Emergent BioSolutions
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Anthrax

Most Recent Events

  • 04 May 2017 Emergent Biosolutions plans a phase III trial for Anthrax
  • 30 Sep 2016 Emergent Biosolutions receives BARDA contract valued at $US1.6 billion for AV 7909
  • 04 Aug 2016 Emergent BioSolutions submits a proposal to the US Department of Health and Human Services recommending AV 7909 as a next generation anthrax vaccine for post-exposure prophylaxis of Anthrax
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top